University of Nottingham-ko ikertzaileekin lankidetzan egindako argitalpenak (20)

2024

  1. 2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice

    Annals of the Rheumatic Diseases, Vol. 83, Núm. 6, pp. 752-759

2023

  1. The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease

    Arthritis and Rheumatology, Vol. 75, Núm. 10, pp. 1703-1713

  2. The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 10, pp. 1248-1257

2022

  1. Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction

    Arthritis Care and Research, Vol. 74, Núm. 10, pp. 1649-1658

2020

  1. 2018 updated European League against Rheumatism evidence-based recommendations for the diagnosis of gout

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 1, pp. 31-38

2019

  1. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 11, pp. 1592-1600

2017

  1. 2016 updated EULAR evidence-based recommendations for the management of gout

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 1, pp. 29-42

  2. Treat-To-Target (T2T) recommendations for gout

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 4, pp. 632-638

2015

  1. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013

    The Lancet, Vol. 386, Núm. 10010, pp. 2287-2323

  2. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013

    The Lancet, Vol. 386, Núm. 9995, pp. 743-800

2014

  1. Improving cardiovascular and renal outcomes in gout: What should we target?

    Nature Reviews Rheumatology, Vol. 10, Núm. 11, pp. 654-661

  2. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): A large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia

    BMJ Open, Vol. 4, Núm. 7

  3. Up-titration of allopurinol in patients with gout

    Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 1, pp. 25-30

2012

  1. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2197-2223

  2. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2163-2196

2011

  1. EULAR recommendations for calcium pyrophosphate deposition. Part II: Management

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 4, pp. 571-575

  2. European league against rheumatism recommendations for calcium pyrophosphate deposition. Part I: Terminology and diagnosis

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 4, pp. 563-570

2010

  1. International position paper on febuxostat

    Clinical Rheumatology, Vol. 29, Núm. 8, pp. 835-840

2006

  1. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT)

    Annals of the Rheumatic Diseases, Vol. 65, Núm. 10, pp. 1301-1311

  2. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

    Annals of the Rheumatic Diseases, Vol. 65, Núm. 10, pp. 1312-1324